Gene therapy: evidence, value and affordability in the US health care system | Zendy

Grace Hampson | Zendy; Adrian Towse | Zendy; Steven D. Pearson | Zendy; William B Dreitlein | Zendy; Chris Henshall | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gene therapy: evidence, value and affordability in the US health care system

Author(s) -

Grace Hampson,

Adrian Towse,

Steven D. Pearson,

William B Dreitlein,

Chris Henshall

Publication year - 2017

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2017-0068

Subject(s) - medicine , value (mathematics) , health care , healthcare system , alternative medicine , public relations , political science , economic growth , pathology , economics , machine learning , computer science

Aims: To explore the challenges presented by gene therapies, discuss potential solutions, and present policy recommendations. Methods: A review of the literature and series of expert interviews were conducted and discussed at a Policy Forum convened by The Institute for Clinical and Economic Review (ICER). The Policy Forum was attended by independent experts and senior representatives from 20 payer organizations and life sciences companies. Results: Three categories of challenges are identified: evidence generation, assessing value and affordability. Possible solutions and policy recommendations are presented for each of the three main categories of challenges. Conclusions: Gene therapies present exciting opportunities, but also pose major challenges. Dialogue between manufacturers and payers around the issues and possible solutions is crucial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research